Emmanuel Spaggiari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emmanuel Spaggiari has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Sophie Dreux
Department of Biochemistry and Hormonology, Robert Debré Hospital, AP-HP, Paris, France
4 shared publicationsAnne‐Lise Delezoide
Developmental Biology AP‐HP, Robert Debré Hospital Paris France
3 shared publicationsF. Guimiot
Department of Developmental Biology, Robert Debré Hospital, AP-HP, Paris, France
3 shared publicationsF. Muller
Department of Biochemistry and Hormonology, Robert Debré Hospital, AP-HP, Paris, France
3 shared publicationsFrançoise Muller
Biochemistry and Hormonology, Robert Debré Hospital AP‐HP Paris France
3 shared publicationsIsabelle Czerkiewicz
Department of Biochemistry‐Hormonology Robert Debré Hospital, AP‐HP Paris France
3 shared publications
Latest Publications
- 5 August 2019
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 54 (2) , 279-280
Contribution of three‐dimensional ultrasound and three‐dimensional helical computed tomography to prenatal diagnosis of Stickler syndrome
- 5 August 2019
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 54 (2) , 279-280
Contribution of three‐dimensional ultrasound and three‐dimensional helical computed tomography to prenatal diagnosis of Stickler syndrome
- 12 April 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (8) , 555-560
Comparison of biochemical analysis of fetal serum and fetal urine in the prediction of postnatal renal outcome in lower urinary tract obstruction
Objectives: To compare the prognostic value of fetal serum biochemistry and fetal urine biochemistry in predicting renal outcome in lower urinary tract obstruction (LUTO).Methods: We retrospectively studied renal outcome following a prenatal diagnosis of LUTO in cases for which both fetal blood and fetal urine were sampled. We classified the renal outcome as either “favorable,” when postnatal renal function was normal, or “adverse,” in the case of postnatal chronic renal failure or when renal histological lesions were present at autopsy in the case of termination of pregnancy. A prognostic model was constructed for urine and serum separately. β2‐Microglobulin was the only remaining independent predictor in fetal urine. β2‐Microglobulin in serum and urine were compared by using receiver operating characteristic curves.Results: In the 50 cases included, the rate of adverse outcome was 34 of 50(68%): autopsy confirmed severity of renal disease in all 27 cases who underwent termination of pregnancy, and among the 23 live born children, 7 developed renal failure. Fetal serum and urine markers were all significantly associated with renal outcome (P < .01). The receiver operating characteristic curves for fetal serum and fetal urinary β2‐microglobulin were similar (area under the curve = 0.908 versus 0.909, P = .96).Conclusion: Fetal serum biochemistry and fetal urine biochemistry are of similar prognostic value in predicting postnatal renal outcome in fetuses with LUTO.
- 12 April 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (8) , 555-560
Comparison of biochemical analysis of fetal serum and fetal urine in the prediction of postnatal renal outcome in lower urinary tract obstruction
Objectives: To compare the prognostic value of fetal serum biochemistry and fetal urine biochemistry in predicting renal outcome in lower urinary tract obstruction (LUTO).Methods: We retrospectively studied renal outcome following a prenatal diagnosis of LUTO in cases for which both fetal blood and fetal urine were sampled. We classified the renal outcome as either “favorable,” when postnatal renal function was normal, or “adverse,” in the case of postnatal chronic renal failure or when renal histological lesions were present at autopsy in the case of termination of pregnancy. A prognostic model was constructed for urine and serum separately. β2‐Microglobulin was the only remaining independent predictor in fetal urine. β2‐Microglobulin in serum and urine were compared by using receiver operating characteristic curves.Results: In the 50 cases included, the rate of adverse outcome was 34 of 50(68%): autopsy confirmed severity of renal disease in all 27 cases who underwent termination of pregnancy, and among the 23 live born children, 7 developed renal failure. Fetal serum and urine markers were all significantly associated with renal outcome (P < .01). The receiver operating characteristic curves for fetal serum and fetal urinary β2‐microglobulin were similar (area under the curve = 0.908 versus 0.909, P = .96).Conclusion: Fetal serum biochemistry and fetal urine biochemistry are of similar prognostic value in predicting postnatal renal outcome in fetuses with LUTO.
- 28 April 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (7) , 673-679
Impact on spina bifida screening of shifting prenatal Down syndrome maternal serum screening from the second trimester to the first
Objectives: Shifting screening for trisomy 21 to the first trimester has resulted in the loss of maternal serum alpha‐fetoprotein screening for spina bifida. The aim of this study was to study the impact on open spina bifida prenatal screening.Study design: We reviewed prenatally diagnosed cases of spina bifida over three years: 2009 (only second‐trimester screening, MSM2T), 2010 (transient period) and 2011 (majority first‐trimester screening, MSM1T). Cases were assigned to three groups based on maternal serum markers (MSM2T, MSM1T and ‘not performed’). Gestational age at diagnosis of spina bifida was compared between these three groups and between the years 2009 and 2011.Results: Median gestational ages at diagnosis of the 742 spina bifida cases between the three groups were 22 weeks [18+6–23], 22+1 weeks [21+3–23] and 21+4 weeks [14+1–23], respectively (P < 0.005). The diagnosis was made at 14–20 weeks in 34.7% for MSM2T group versus 8.5% for MSM1T (P < 0.001). Spina bifida diagnosis at 14–20 weeks declined from 38.8% in 2009 to 13.3% in 2011 (P < 0.001).Conclusion: Loss of maternal serum alpha‐fetoprotein had a tangible effect on the gestational age at diagnosis of spina bifida and resulted in a decrease of 25% of cases of spina bifida detected before 20 weeks. © 2017 John Wiley & Sons, Ltd.
- 28 April 2017
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (7) , 673-679
Impact on spina bifida screening of shifting prenatal Down syndrome maternal serum screening from the second trimester to the first
Objectives: Shifting screening for trisomy 21 to the first trimester has resulted in the loss of maternal serum alpha‐fetoprotein screening for spina bifida. The aim of this study was to study the impact on open spina bifida prenatal screening.Study design: We reviewed prenatally diagnosed cases of spina bifida over three years: 2009 (only second‐trimester screening, MSM2T), 2010 (transient period) and 2011 (majority first‐trimester screening, MSM1T). Cases were assigned to three groups based on maternal serum markers (MSM2T, MSM1T and ‘not performed’). Gestational age at diagnosis of spina bifida was compared between these three groups and between the years 2009 and 2011.Results: Median gestational ages at diagnosis of the 742 spina bifida cases between the three groups were 22 weeks [18+6–23], 22+1 weeks [21+3–23] and 21+4 weeks [14+1–23], respectively (P < 0.005). The diagnosis was made at 14–20 weeks in 34.7% for MSM2T group versus 8.5% for MSM1T (P < 0.001). Spina bifida diagnosis at 14–20 weeks declined from 38.8% in 2009 to 13.3% in 2011 (P < 0.001).Conclusion: Loss of maternal serum alpha‐fetoprotein had a tangible effect on the gestational age at diagnosis of spina bifida and resulted in a decrease of 25% of cases of spina bifida detected before 20 weeks. © 2017 John Wiley & Sons, Ltd.
- 29 March 2017
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 49 (5) , 617-622
Sequential fetal serum β2‐microglobulin to predict postnatal renal function in bilateral or low urinary tract obstruction
Objective: Fetal serum β2‐microglobulin has been shown to predict postnatal renal outcome in cases of fetal obstructive uropathy. We assessed the value of serial measurements of fetal serum β2‐microglobulin in the prediction of postnatal renal outcome.Methods: We retrospectively studied renal outcome in 42 fetuses with bilateral or low urinary tract obstruction that had fetal blood sampling on at least two occasions to assay serum levels of β2‐microglobulin. Amniotic fluid volume at the time of each sampling was recorded. We classified renal outcome as either favorable (when postnatal renal function was normal) or adverse (when postnatal chronic renal failure occurred or when renal dysplasia at autopsy was noted). A β2‐microglobulin cut‐off of 5 mg/L and amniotic fluid index of 5 cm were used to predict postnatal renal outcome.Results: Renal outcome was adverse in 28 cases and favorable in 14. In 12 (28.6%) cases, fetal serum β2‐microglobulin concentration differed between the first and last measurement. Prediction of postnatal renal outcome was correct in 11 of these cases based on the last β2‐microglobulin measurement. The sensitivity of β2‐microglobulin in predicting renal outcome was significantly higher (P = 0.005) when using the last rather than the first measurement (96.4% vs 64.3%), with similar specificity for both measurements (85.7% vs 78.6%, non‐significant). The sensitivity of amniotic fluid volume was also significantly higher (P = 0.005) when using the last rather than the first measurement (75.0% vs 35.7%), with similar specificity for both measurements (64.3% vs 71.4%, non‐significant).Conclusion: Sequential measurement of serum β2‐microglobulin, performed for adverse ultrasound findings, such as renal parenchymal abnormality or decreasing amniotic fluid volume, predicts postnatal renal outcome more accurately than does a single assay. This may be due to possible worsening of renal injury with increasing duration of urinary tract obstruction. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.
- 29 March 2017
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 49 (5) , 617-622
Sequential fetal serum β2‐microglobulin to predict postnatal renal function in bilateral or low urinary tract obstruction
Objective: Fetal serum β2‐microglobulin has been shown to predict postnatal renal outcome in cases of fetal obstructive uropathy. We assessed the value of serial measurements of fetal serum β2‐microglobulin in the prediction of postnatal renal outcome.Methods: We retrospectively studied renal outcome in 42 fetuses with bilateral or low urinary tract obstruction that had fetal blood sampling on at least two occasions to assay serum levels of β2‐microglobulin. Amniotic fluid volume at the time of each sampling was recorded. We classified renal outcome as either favorable (when postnatal renal function was normal) or adverse (when postnatal chronic renal failure occurred or when renal dysplasia at autopsy was noted). A β2‐microglobulin cut‐off of 5 mg/L and amniotic fluid index of 5 cm were used to predict postnatal renal outcome.Results: Renal outcome was adverse in 28 cases and favorable in 14. In 12 (28.6%) cases, fetal serum β2‐microglobulin concentration differed between the first and last measurement. Prediction of postnatal renal outcome was correct in 11 of these cases based on the last β2‐microglobulin measurement. The sensitivity of β2‐microglobulin in predicting renal outcome was significantly higher (P = 0.005) when using the last rather than the first measurement (96.4% vs 64.3%), with similar specificity for both measurements (85.7% vs 78.6%, non‐significant). The sensitivity of amniotic fluid volume was also significantly higher (P = 0.005) when using the last rather than the first measurement (75.0% vs 35.7%), with similar specificity for both measurements (64.3% vs 71.4%, non‐significant).Conclusion: Sequential measurement of serum β2‐microglobulin, performed for adverse ultrasound findings, such as renal parenchymal abnormality or decreasing amniotic fluid volume, predicts postnatal renal outcome more accurately than does a single assay. This may be due to possible worsening of renal injury with increasing duration of urinary tract obstruction. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.
- 7 February 2017
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 49 (2) , 277-278
Pitfall in first-trimester diagnosis of chorionicity in twin pregnancy
- 7 February 2017
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 49 (2) , 277-278
Pitfall in first-trimester diagnosis of chorionicity in twin pregnancy
- 5 October 2015
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 170 (1) , 239-242
First fetal case of the 8q24.3 contiguous genes syndrome
Molecular cytogenetics, particularly array‐CGH, opened the way to the « genotype first approach » and for the discovery of new micro rearrangement syndromes. This was the case for the 8q24.3 microdeletion syndrome. Here, we describe the phenotype of a fetus with a 8q24.3 deletion. This rare condition has to be considered as a contiguous genes syndrome because its phenotype is generated by the SCRIB and PUF60 adjacent gene endophenotypes. The fetus presented atrioventricular septal defect and hypoplastic aortic arch, facial dysmorphism, microretrognathia, dysmorphic ears, clinodactyly of the 5th digit on both hands, mild rocker bottom feet and abnormal third sacral vertebra. This fetus is the first case where the endophenotype produced by SCRIB gene is absent. This case is compared with the previous published cases.
- 5 October 2015
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 170 (1) , 239-242
First fetal case of the 8q24.3 contiguous genes syndrome
Molecular cytogenetics, particularly array‐CGH, opened the way to the « genotype first approach » and for the discovery of new micro rearrangement syndromes. This was the case for the 8q24.3 microdeletion syndrome. Here, we describe the phenotype of a fetus with a 8q24.3 deletion. This rare condition has to be considered as a contiguous genes syndrome because its phenotype is generated by the SCRIB and PUF60 adjacent gene endophenotypes. The fetus presented atrioventricular septal defect and hypoplastic aortic arch, facial dysmorphism, microretrognathia, dysmorphic ears, clinodactyly of the 5th digit on both hands, mild rocker bottom feet and abnormal third sacral vertebra. This fetus is the first case where the endophenotype produced by SCRIB gene is absent. This case is compared with the previous published cases.
- 8 June 2015
- Published by Wiley in Prenatal Diagnosis
- Vol. 35 (9) , 888-893
Performance of prenatal diagnosis in esophageal atresia
Objective: The aim of this study was to evaluate the performance of prenatal diagnosis of esophageal atresia (EA) and its associated abnormalities.Methods: We conducted a retrospective study from a pediatric database of EA managed postnatally in a single center. Prenatal data included ultrasound and magnetic resonance imaging parameters including amniotic fluid (AF) volume, stomach visualization, AF biochemistry, and associated malformations. Postnatal data included type of EA, mortality, and postnatal diagnosis of associated malformations.Results: One hundred twenty‐two cases were included. The diagnosis was suspected prenatally in 39/122 (32%) cases. Polyhydramnios was noted in 64/122 (52.4%), and the stomach was not visualized or small in 39 (32%). There was 14 (11.5%), 2 (1.6%), 101 (82.8%), 5 (4.1%), and 0 (0%) types I, II, III, IV, and V, respectively. EA was suspected prenatally in 12/14 (85.7%) in type I and in 27/108 (25%) in cases with tracheoesophageal fistula (II + III + IV + V). Magnetic resonance imaging was performed in 28 cases, which confirmed EA in 19/28 (sensitivity 67.8%). AF biochemistry was performed in 17 cases, which confirmed EA in 15/17 (sensitivity 88.2%) cases. Of the 69 syndromic associations, 41/69 (59.4%) cases were detected prenatally. Associated malformation was a strong predictor of postnatal death [19/69 vs 3/53, odds ratio 6.33 (1.76; 22.75), p < 0.01].Conclusion: Prenatal diagnosis of EA remains challenging. MRI and AF biochemistry may prove useful in the diagnosis of EA. Prenatal ultrasound and MRI examination should also focus on associated anomalies. © 2015 John Wiley & Sons, Ltd.
- 8 June 2015
- Published by Wiley in Prenatal Diagnosis
- Vol. 35 (9) , 888-893
Performance of prenatal diagnosis in esophageal atresia
Objective: The aim of this study was to evaluate the performance of prenatal diagnosis of esophageal atresia (EA) and its associated abnormalities.Methods: We conducted a retrospective study from a pediatric database of EA managed postnatally in a single center. Prenatal data included ultrasound and magnetic resonance imaging parameters including amniotic fluid (AF) volume, stomach visualization, AF biochemistry, and associated malformations. Postnatal data included type of EA, mortality, and postnatal diagnosis of associated malformations.Results: One hundred twenty‐two cases were included. The diagnosis was suspected prenatally in 39/122 (32%) cases. Polyhydramnios was noted in 64/122 (52.4%), and the stomach was not visualized or small in 39 (32%). There was 14 (11.5%), 2 (1.6%), 101 (82.8%), 5 (4.1%), and 0 (0%) types I, II, III, IV, and V, respectively. EA was suspected prenatally in 12/14 (85.7%) in type I and in 27/108 (25%) in cases with tracheoesophageal fistula (II + III + IV + V). Magnetic resonance imaging was performed in 28 cases, which confirmed EA in 19/28 (sensitivity 67.8%). AF biochemistry was performed in 17 cases, which confirmed EA in 15/17 (sensitivity 88.2%) cases. Of the 69 syndromic associations, 41/69 (59.4%) cases were detected prenatally. Associated malformation was a strong predictor of postnatal death [19/69 vs 3/53, odds ratio 6.33 (1.76; 22.75), p < 0.01].Conclusion: Prenatal diagnosis of EA remains challenging. MRI and AF biochemistry may prove useful in the diagnosis of EA. Prenatal ultrasound and MRI examination should also focus on associated anomalies. © 2015 John Wiley & Sons, Ltd.
- 13 August 2013
- Published by Wiley in Prenatal Diagnosis
- Vol. 33 (12) , 1167-1172
Outcome following prenatal diagnosis of severe bilateral renal hypoplasia
Objective The aim of this research was to evaluate the outcome and prognostic value of fetal serum β2-microglobulin in case of prenatal diagnosis of severe bilateral renal hypoplasia. Methods Cases of hypoplastic kidneys were detected on ultrasound and referred to our laboratory for determination of fetal blood β2-microglobulin, over a 12-year period. Prenatal prognostic assessment was based upon amniotic fluid volume and fetal serum β2-microglobulin (cut-off: 5 mg/L). Outcome measures were postnatal renal function or renal pathological features when termination of pregnancy (TOP) and genetic studies were performed. Results A total of 34 cases were identified; 13 (38%) were liveborn and 21 (62%) underwent TOP. Renal hypoplasia was confirmed postnatally in all cases. Oligohydramnios/anhydramnios was observed in 30/34 (88%) cases. Associated genetic or anatomical anomalies were found in 8/34 (24%) cases. Renal function of liveborn infants was normal in 4/13 cases. Renal lesions were observed in all TOPs (21/21 cases). Overall, 30/34 (88.2%) cases had a poor outcome. β2-microglobulin accurately predicts poor renal outcome in 27/31 (87.1%) cases. β2-microglobulin was not interpretable in three cases due to amniotic fluid contamination. The prognostic value of β2-microglobulin was similar to that of amniotic fluid volume assessment. Conclusion Hypoplastic kidneys complicated by oligohydramnios/anhydramnios are associated with poor outcome. Fetal serum β2-microglobulin and oligohydramnios both predicted poor outcome. © 2013 John Wiley & Sons, Ltd.
- 13 August 2013
- Published by Wiley in Prenatal Diagnosis
- Vol. 33 (12) , 1167-1172
Outcome following prenatal diagnosis of severe bilateral renal hypoplasia
Objective The aim of this research was to evaluate the outcome and prognostic value of fetal serum β2-microglobulin in case of prenatal diagnosis of severe bilateral renal hypoplasia. Methods Cases of hypoplastic kidneys were detected on ultrasound and referred to our laboratory for determination of fetal blood β2-microglobulin, over a 12-year period. Prenatal prognostic assessment was based upon amniotic fluid volume and fetal serum β2-microglobulin (cut-off: 5 mg/L). Outcome measures were postnatal renal function or renal pathological features when termination of pregnancy (TOP) and genetic studies were performed. Results A total of 34 cases were identified; 13 (38%) were liveborn and 21 (62%) underwent TOP. Renal hypoplasia was confirmed postnatally in all cases. Oligohydramnios/anhydramnios was observed in 30/34 (88%) cases. Associated genetic or anatomical anomalies were found in 8/34 (24%) cases. Renal function of liveborn infants was normal in 4/13 cases. Renal lesions were observed in all TOPs (21/21 cases). Overall, 30/34 (88.2%) cases had a poor outcome. β2-microglobulin accurately predicts poor renal outcome in 27/31 (87.1%) cases. β2-microglobulin was not interpretable in three cases due to amniotic fluid contamination. The prognostic value of β2-microglobulin was similar to that of amniotic fluid volume assessment. Conclusion Hypoplastic kidneys complicated by oligohydramnios/anhydramnios are associated with poor outcome. Fetal serum β2-microglobulin and oligohydramnios both predicted poor outcome. © 2013 John Wiley & Sons, Ltd.
- 13 August 2013
- Published by Wiley in Prenatal Diagnosis
- Vol. 33 (12) , 1162-1166
Outcome and etiologies of fetal megacystis according to the gestational age at diagnosis
Objective: To investigate the gestational age‐specific outcomes and the different etiologies of megacystis diagnosed at screening ultrasound.Methods: A retrospective single‐center study was conducted between 1989 and 2009. We identified all consecutive cases of megacystis prenatally diagnosed during routine ultrasound screening. Outcome, final diagnosis, and renal function were recorded.Results: Eighty‐four patients were included. An isolated lower urinary tract obstruction was observed in 38/84 (45.2%), ureterovesical reflux in 9/84 (10.7%), an associated congenital abnormality in 32/84 (38.1%) and a normal bladder in 5/84 (6%). Increased gestational age at diagnosis was correlated with an increased rate of live born children (P < 0.01). No cases of megacystis diagnosed in the first trimester were born alive. When diagnosis of posterior urethral valves (PUV) was made in the third trimester, the ultimate survival rate was 11/13 (84.6%) compared with 3/12 (25%) for a diagnosis made in the second trimester (P = 0.02).Conclusion: Lower urinary tract obstruction is the main etiology of megacystis. Megacystis can also be part of more complex malformations. Outcome of megacystis detected in the first trimester is poor. PUV detected in the third trimester had a better overall survival rate than PUV detected in the second trimester. © 2013 John Wiley & Sons, Ltd.
- 13 August 2013
- Published by Wiley in Prenatal Diagnosis
- Vol. 33 (12) , 1162-1166
Outcome and etiologies of fetal megacystis according to the gestational age at diagnosis
Objective: To investigate the gestational age‐specific outcomes and the different etiologies of megacystis diagnosed at screening ultrasound.Methods: A retrospective single‐center study was conducted between 1989 and 2009. We identified all consecutive cases of megacystis prenatally diagnosed during routine ultrasound screening. Outcome, final diagnosis, and renal function were recorded.Results: Eighty‐four patients were included. An isolated lower urinary tract obstruction was observed in 38/84 (45.2%), ureterovesical reflux in 9/84 (10.7%), an associated congenital abnormality in 32/84 (38.1%) and a normal bladder in 5/84 (6%). Increased gestational age at diagnosis was correlated with an increased rate of live born children (P < 0.01). No cases of megacystis diagnosed in the first trimester were born alive. When diagnosis of posterior urethral valves (PUV) was made in the third trimester, the ultimate survival rate was 11/13 (84.6%) compared with 3/12 (25%) for a diagnosis made in the second trimester (P = 0.02).Conclusion: Lower urinary tract obstruction is the main etiology of megacystis. Megacystis can also be part of more complex malformations. Outcome of megacystis detected in the first trimester is poor. PUV detected in the third trimester had a better overall survival rate than PUV detected in the second trimester. © 2013 John Wiley & Sons, Ltd.
- 1 June 2013
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 56 (6) , 297-300
Mowat–Wilson syndrome in a fetus with antenatal diagnosis of short corpus callosum: Advocacy for standard autopsy
- 1 June 2013
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 56 (6) , 297-300
Mowat–Wilson syndrome in a fetus with antenatal diagnosis of short corpus callosum: Advocacy for standard autopsy